Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Intercytex

Explore full profile

Biotechnology company developing cell-based therapies for the repair and regeneration of skin and hair

Manchester, United KingdomFounded 2000Biotech & Life Sciences
Valuation $79M Market cap · 2006

About Intercytex

Intercytex Ltd. is a pioneering regenerative medicine company based in the United Kingdom, focused on developing innovative, cell-based therapies that restore and regenerate human tissues, founded in 2000, the company has positioned itself at the forefront of skin and hair regeneration, leveraging the power of living human cells to address critical unmet medical needs in dermatology and aesthetic medicine, its flagship product, ICX-RHY, is a human dermal fibroblast therapy designed to treat conditions such as epidermolysis bullosa, burn scars, and age-related skin deterioration, by stimulating natural dermal repair, another leading product in its pipeline is ICX-TRC, an injectable therapy aimed at regenerating hair follicles, offering a novel, biological solution to hair loss that moves beyond traditional cosmetic treatments, with headquarters in Manchester and GMP-compliant manufacturing facilities, Intercytex is equipped to support clinical-grade cell processing and scalable product development, backed by a strong intellectual property portfolio of over 100 patents, the company has raised more than $20 million in funding through seed rounds, venture capital, and a successful IPO, its partnerships with academic institutions and research organizations further strengthen its research and development capabilities, particularly in areas such as stem cell science and wound healing, Intercytex remains committed to transforming the field of regenerative medicine by offering therapies that don’t just manage symptoms, but actually stimulate the body’s own ability to heal, its vision is to create effective, scalable, and accessible treatments for skin damage, scarring, and hair loss, redefining how these conditions are treated through the application of advanced biomedical science and cell therapy innovation.

Keywords and Tags: regenerative medicine, cell therapy, hair regeneration, skin regeneration, wound healing, tissue engineering, dermal fibroblasts, epidermolysis bullosa treatment, burn scar repair, hair loss therapy, living cell therapy, injectable cell therapy, hair follicle regeneration, GMP manufacturing, clinical-stage biotech, dermatology innovation, stem cells, biomedical innovation, health technology, regenerativemedicine, celltherapy, hairregeneration, skinrepair, woundhealing, biotechinnovation, tissueengineering, stemcells, clinicaltrials, dermatology, hairlosstreatment, aestheticmedicine, biomedicalscience, medicalinnovation, healthtech.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2000
Headquarters
Manchester, United Kingdom
Listing
IPO 2006
Employees
7
Open positions
None listed
Dealroom signal
0.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Dermatology, Spinout, Cell Therapy, DT and LS, uk is8 life sciences, UKSU, science-based
Client focus
b2c
Investment activity
1 company, latest Dec 2008
Capital deployed
—
Preferred round
ACQUISITION

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Sep 2008 $3.6M — Undisclosed ↗
IPO✓Exit Feb 2006 $20M $79M Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Intercytex website traffic

Latest recorded traffic for Intercytex is 160 monthly website visits, down 42.9% over the last three months. Intercytex's team grew 16.7% over the past year.

Latest monthly visits160 3-month web change-42.9% 1-year team growth+16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later5 investors entered at this stage

  • Avlar BioVentures
  • NIF Ventures
  • Scottish Equity Partners
  • 3i Group
  • Excalibur Fund Managers

Other known investors2 additional known investors

  • University College London
  • Omega Funds
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Intercytex on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intercytex’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.